Post Profile






Ribociclib improves progression-free survival in advanced breast cancer

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders

Health : EurekAlert: Health

(European Society for Medical Oncology) The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tu...

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

Health : EurekAlert: Health

(European Society for Medical Oncology) The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first ti...

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Health : EurekAlert: Health

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the fir...

Ribociclib Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of po...

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, rese...

Comments


Copyright © 2016 Regator, LLC